Cyramza

What Cyramza is used for

Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Non-small cell lung cancer Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Hepatocellular carcinoma Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of … (the exact criteria are in the official EMA product information).

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Cyramza

Active substance

ramucirumab

Disease area

Stomach Neoplasms

Medicine group

Antineoplastic agents

ATC code

L01FX06

Marketing authorisation holder

Eli Lilly Nederland B.V.

Authorised in the EU since

2014

Official information

• Cyramza: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Cyramza

In India

• Ramucirumab: 2 brands in India